hormone therapy

The role of the 6PGD protein in prostate cancer hormone treatment resistance

The role of the 6PGD protein in prostate cancer hormone treatment resistance

A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth.
Gillis JL, Hinneh JA, Ryan NK, Irani S, Moldovan M, Quek LE, Shrestha RK, Hanson AR, Xie J, Hoy AJ, Holst J, Centenera MM, Mills IG, Lynn DJ, Selth LA, Butler LM. Elife. 2021 Aug 12;10:e62592. doi: 10.7554/eLife.62592. PMID: 34382934.
Contact: Luke Selth

Androgen receptor (AR) signalling and drug resistance in prostate cancer

Androgen receptor (AR) signalling and drug resistance in prostate cancer

The androgen receptor (AR) is a key protein in prostate cells that binds androgen sex hormones (e.g. testosterone) that drive prostate cancer development and progression. We are leading research developing and trialling new androgen receptor targeted drugs to combat drug resistance and fatal disease.

The University of Adelaide
Contact:
Professor Lisa Butler, Associate Professor Luke Selth